RU 105

Drug Profile

RU 105

Alternative Names: DE-105

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Santen Pharmaceutical
  • Class Eye disorder therapies; Kinins; Nerve growth factors; Neuropeptides; Somatomedins
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Corneal disorders

Most Recent Events

  • 07 Dec 2015 R-Tech Ueno has been acquired and merged into Sucampo Pharmaceuticals
  • 24 Apr 2015 RU 105 is still in phase I trials for Corneal disorders in USA
  • 24 Apr 2015 RU 105 is still in phase II trials for Corneal disorders in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top